QureTech Bio

Quretech Bio - defeats bacterial virulence

Since World War II, antibiotics have been the most effective factor in longevity and population expansion. Today, loss of effective antibiotics threatens our medical institutions – antibiotic resistance is a serious problem already or will be within the decade. Doctors, in the US and UK, have reported that they now have less than a handful effective antibiotics for some pathogens. In the EU alone, infections with multidrug resistant bacteria cause around 25,000 deaths each year and the associated economic burden is immense. Still in today’s world, more infants and children are dying from pneumonia than from malaria.

QureTech Bio’s vision is to develop first line drugs to combat antibiotic resistance and infectious diseases. The global market for antibiotics is estimated at USD 38 billion with USA, Europe and Japan representing 50%. The cost of antibiotic resistance to medical communities in the EU alone is conservatively estimated to be €1.5 billion and the availability of new targeted antibiotics of this type would generate significant cost savings for healthcare systems.

New types of antibiotics to tackle resistant bacteria are urgently needed, yet there is an almost empty drug pipeline with few early stage drugs under development. Scientific and industrial communities must develop new antibiotic drugs, and there must be a drive towards developing novel antibiotics with alternative modes of action.

Hult1

Current projects

Today it is once again World TB Day. If we do not manage to create new safe and effective treatments of Multi Drug Resistant Tuberculosis we will have to highlight this event for a long time. Without new effective treatments for Multi Drug Resistant Tuberculosis the estimate is that this will have taken 75 million lives by 2050 at a cost to society corresponding the GDP of EU.

QureTech Bio have discovered fundamentally new approach to target Mutli Drug Resistant Tuberculosis and are developing a drug based on this concept that outclass resistance against certain important drugs against Tuberculosis.
... See MoreSee Less

Today is World Tuberculosis Day! Tuberculosis is the top infectious disease killer in the world. In 2016, 1.7 million people died from TB. Tuberculosis is the main cause of deaths related to antimicrobial resistance and the leading killer of people with HIV. We need to unite to End TB!

View on Facebook

LifeSienceStafetten är i Umeå idag och temat är antibiotikaresistens. Jennie Ekbeck, vd för Umeå Biotech Incubator inleder.
QureTech Bio representeras av Jörgen Johansson och Fritiof Pontén.
... See MoreSee Less

View on Facebook